{
  "id": "5c960f21ecadf2e73f000020",
  "type": "factoid",
  "question": "What are DMARDs?",
  "ideal_answer": "To determine the utility of ultrasonography in guiding modification of disease-modifying anti-rheumatic drug (DMARD) and steroid therapy for inflammatory arthritis (IA)",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22420649",
    "http://www.ncbi.nlm.nih.gov/pubmed/20681888",
    "http://www.ncbi.nlm.nih.gov/pubmed/27604908",
    "http://www.ncbi.nlm.nih.gov/pubmed/28324149",
    "http://www.ncbi.nlm.nih.gov/pubmed/7732491",
    "http://www.ncbi.nlm.nih.gov/pubmed/25603037",
    "http://www.ncbi.nlm.nih.gov/pubmed/25630309",
    "http://www.ncbi.nlm.nih.gov/pubmed/27538766",
    "http://www.ncbi.nlm.nih.gov/pubmed/25244345",
    "http://www.ncbi.nlm.nih.gov/pubmed/25943001",
    "http://www.ncbi.nlm.nih.gov/pubmed/25943002",
    "http://www.ncbi.nlm.nih.gov/pubmed/22298075",
    "http://www.ncbi.nlm.nih.gov/pubmed/24129128",
    "http://www.ncbi.nlm.nih.gov/pubmed/9608316",
    "http://www.ncbi.nlm.nih.gov/pubmed/18824833",
    "http://www.ncbi.nlm.nih.gov/pubmed/30448932",
    "http://www.ncbi.nlm.nih.gov/pubmed/25504789",
    "http://www.ncbi.nlm.nih.gov/pubmed/24470443",
    "http://www.ncbi.nlm.nih.gov/pubmed/23959574",
    "http://www.ncbi.nlm.nih.gov/pubmed/23961667",
    "http://www.ncbi.nlm.nih.gov/pubmed/28679392",
    "http://www.ncbi.nlm.nih.gov/pubmed/12468815",
    "http://www.ncbi.nlm.nih.gov/pubmed/23716132"
  ],
  "snippets": [
    {
      "text": "To determine the utility of ultrasonography in guiding modification of disease-modifying anti-rheumatic drug (DMARD) and steroid therapy for inflammatory arthritis (IA)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27538766",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "disease-modifying antirheumatic drugs (DMARDs)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27604908",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with disease-modifying antirheumatic drugs (DMARDs) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28324149",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[DMARDs (disease-modifying antirheumatic drugs)].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23961667",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Disease-modifying antirheumatic drugs (DMARDs) have largely contributed to recent paradigm shift of rheumatoid arthritis (RA) treatment strategy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23961667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nBiologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28679392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25630309",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nRheumatoid arthritis (RA) is a progressive autoimmune disorder of joints that is associated with high health care costs, yet guidance is lacking on how early to initiate biologic disease-modifying antirheumatic drugs (DMARDs), a class of medications that is the major cost driver in RA management.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nTherapy of rheumatoid arthritis (RA) is typically characterized by the sequential use of disease-modifying anti-rheumatic drugs (DMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12468815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There are only six DMARDs (disease modifying anti-rheumatic drugs) available in the clinical practice, such as gold sodium thiomalate, D-penicillamine, bucillamine, auranofin, salazosulphapyridine, and lobenzarit disodium.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7732491",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tofacitinib (Xeljanz(\u00ae)) is the first approved drug in a new class of disease modifying antirheumatic drugs (DMARDs), the Janus kinase (JAK) inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23716132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nDisease-modifying antirheumatic drugs (DMARDs) are the standard of care for rheumatoid arthritis (RA); however, studies have found that many patients do not receive them.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24470443",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of rheumatoid arthritis (RA) pharmacotherapy and should be initiated promptly after RA diagnosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23959574",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\nWhen rheumatoid arthritis (RA) patients have achieved sustained good clinical responses can their disease-modifying anti-rheumatic drugs (DMARDs) be reduced or discontinued?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24129128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nGiven the availability of a number of alternative biologic treatment options and other novel disease-modifying antirheumatic drugs (DMARDs) for the treatment of patients with rheumatoid arthritis (RA), clinicians are faced with an increasingly challenging choice regarding optimal treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25943002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nTreatment of juvenile idiopathic arthritis (JIA) with disease-modifying antirheumatic drugs (DMARDs) may improve outcomes compared to conventional therapy (e.g., non-steroidal anti-inflammatory drugs, intra-articular corticosteroids).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22420649",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disease modifying antirheumatic drugs (DMARDs) is a category of drugs which is used as medication in various arthritic conditions to arrest the progression of disease along with relief from pain.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25244345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For this purpose, all patients with the diagnosis of RA should be treated by disease-modifying antirheumatic drugs (DMARDs) including biologic DMARDs and non-biologic DMARDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22298075",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(2) What is the search volume for disease-modifying antirheumatic drugs (DMARDs)?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30448932",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>OBJECTIVES</b>: Patients and rheumatologists have a number of options to consider for the treatment of rheumatoid arthritis (RA), including biologic response modifier (BRM) therapy and diseasemodifying antirheumatic drugs (DMARDs).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824833",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To explore what considerations patients have when deciding about disease-modifying antirheumatic drugs (DMARDs) and what information patients need to participate in the decision-making process.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25504789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Disease-modifying antirheumatic drug (DMARD) therapy is now clearly accepted as the primary treatment for rheumatoid arthritis, with an increasing emphasis on use of combination therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9608316",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(2) What is the search volume for disease-modifying antirheumatic drugs (DMARDs)?",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30448932",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy of the biologic disease-modifying antirheumatic drugs (DMARDs) shown in clinical trials may be jeopardized due to prevalent poor patient adherence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20681888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although methotrexate has retained its place as the first-line agent, there has been great interest in comparing biologicals to conventional Disease Modifying Anti Rheumatic Drugs (DMARDs) over the past few years with the updated guidelines from both the American College of Rheumatology and European League Against Rheumatism.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25603037",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Disease Modifying anti-rheumatic drugs"
}